We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Accuray (ARAY) Climbs 11.5% as Q1 Earnings Beat Estimates
Read MoreHide Full Article
Accuray Incorporated (ARAY - Free Report) rallied 11.5% on Nov 2 after the company reported first-quarter fiscal 2021 earnings results.
The company reported break-even earnings per share (EPS) in first-quarter fiscal 2021 against the Zacks Consensus Estimate of a loss per share of 9 cents. Also, the company had reported a loss of 11 cents per share a year ago.
Revenue Details
For the fiscal first quarter, net revenues totaled $85.3 million, beating the Zacks Consensus Estimate of $77 million by 8%. On a year-over-year basis, revenues fell 4.8%.
Fiscal Q1 Details
Product Revenues: Product revenues fell 16.6% year over year to $31.3 million in the reported quarter.
Service Revenues: Service revenues totaled $54.1 million, up 4% from the year-ago quarter.
Gross Order Update: Gross orders in the fiscal first quarter totaled $50.5 million, down 35.7% year over year.
Margins
Gross profit in the fiscal first quarter totaled $35.4 million, up 7.5% on a year-over-year basis. Gross margin was 41.5%, highlighting an expansion of 471 basis points (bps) year over year.
Total operating expenses came in at $29.9 million, down 19.6%.
First-quarter operating profit was $5.5 million, down 227.8%. Operating margin came in at 6.4%, highlighting an expansion of 1119 bps.
Accuray Incorporated Price, Consensus and EPS Surprise
The company exited first-quarter fiscal 2021 with total cash and cash equivalents of $89.9 million compared with $107.6 million at the end of the fourth quarter of fiscal 2020.
2021 Guidance
Considering the continued spread of the COVID-19 pandemic and the uncertainty of its impact on the global economy and the healthcare industry, Accuray has decided not to issue any financial guidance for 2021.
Our Take
Accuray exited the fiscal first quarter on a mixed note. The company registered decline in Product revenues in the quarter. We are also concerned about the gross order decline in the quarter.
On the bright side, the company registered growth in Service revenues in the quarter. Solid demand for the Radixact, CyberKnife and TomoTherapy platforms continues to drive the top line. Expansion of both margins is encouraging as well. Recently, the company launched the ClearRT Helical kVCT Imaging for the Radixact System and is gaining positive customer feedback for it.
Zacks Rank and Key Picks
Accuray currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have already announced their quarterly results are Thermo Fisher Scientific Inc. (TMO - Free Report) , Align Technology, Inc. (ALGN - Free Report) and AngioDynamics, Inc. (ANGO - Free Report) . While Thermo Fisher currently sports a Zacks Rank #1 (Strong Buy), the other two carry a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Thermo Fisher reported third-quarter 2020 adjusted EPS of $5.63, beating the Zacks Consensus Estimate by 28.8%. Revenues of $8.52 billion surpassed the consensus mark by 10%.
Align Technology reported third-quarter 2020 adjusted EPS of $2.25, which surpassed the Zacks Consensus Estimate by 281.4%. Revenues of $734.1 million outpaced the consensus mark by 38%.
AngioDynamics reported first-quarter fiscal 2021 adjusted EPS of 2 cents against the Zacks Consensus Estimate of a loss per share of 6 cents. Revenues of $70.2 million beat the consensus mark by 6.9%.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Image: Bigstock
Accuray (ARAY) Climbs 11.5% as Q1 Earnings Beat Estimates
Accuray Incorporated (ARAY - Free Report) rallied 11.5% on Nov 2 after the company reported first-quarter fiscal 2021 earnings results.
The company reported break-even earnings per share (EPS) in first-quarter fiscal 2021 against the Zacks Consensus Estimate of a loss per share of 9 cents. Also, the company had reported a loss of 11 cents per share a year ago.
Revenue Details
For the fiscal first quarter, net revenues totaled $85.3 million, beating the Zacks Consensus Estimate of $77 million by 8%. On a year-over-year basis, revenues fell 4.8%.
Fiscal Q1 Details
Product Revenues: Product revenues fell 16.6% year over year to $31.3 million in the reported quarter.
Service Revenues: Service revenues totaled $54.1 million, up 4% from the year-ago quarter.
Gross Order Update: Gross orders in the fiscal first quarter totaled $50.5 million, down 35.7% year over year.
Margins
Gross profit in the fiscal first quarter totaled $35.4 million, up 7.5% on a year-over-year basis. Gross margin was 41.5%, highlighting an expansion of 471 basis points (bps) year over year.
Total operating expenses came in at $29.9 million, down 19.6%.
First-quarter operating profit was $5.5 million, down 227.8%. Operating margin came in at 6.4%, highlighting an expansion of 1119 bps.
Accuray Incorporated Price, Consensus and EPS Surprise
Accuray Incorporated price-consensus-eps-surprise-chart | Accuray Incorporated Quote
Cash Position
The company exited first-quarter fiscal 2021 with total cash and cash equivalents of $89.9 million compared with $107.6 million at the end of the fourth quarter of fiscal 2020.
2021 Guidance
Considering the continued spread of the COVID-19 pandemic and the uncertainty of its impact on the global economy and the healthcare industry, Accuray has decided not to issue any financial guidance for 2021.
Our Take
Accuray exited the fiscal first quarter on a mixed note. The company registered decline in Product revenues in the quarter. We are also concerned about the gross order decline in the quarter.
On the bright side, the company registered growth in Service revenues in the quarter. Solid demand for the Radixact, CyberKnife and TomoTherapy platforms continues to drive the top line. Expansion of both margins is encouraging as well. Recently, the company launched the ClearRT Helical kVCT Imaging for the Radixact System and is gaining positive customer feedback for it.
Zacks Rank and Key Picks
Accuray currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have already announced their quarterly results are Thermo Fisher Scientific Inc. (TMO - Free Report) , Align Technology, Inc. (ALGN - Free Report) and AngioDynamics, Inc. (ANGO - Free Report) . While Thermo Fisher currently sports a Zacks Rank #1 (Strong Buy), the other two carry a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Thermo Fisher reported third-quarter 2020 adjusted EPS of $5.63, beating the Zacks Consensus Estimate by 28.8%. Revenues of $8.52 billion surpassed the consensus mark by 10%.
Align Technology reported third-quarter 2020 adjusted EPS of $2.25, which surpassed the Zacks Consensus Estimate by 281.4%. Revenues of $734.1 million outpaced the consensus mark by 38%.
AngioDynamics reported first-quarter fiscal 2021 adjusted EPS of 2 cents against the Zacks Consensus Estimate of a loss per share of 6 cents. Revenues of $70.2 million beat the consensus mark by 6.9%.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Download Marijuana Moneymakers FREE >>